Navigation Links
Tragara Pharmaceuticals' Apricoxib Reverses EMT, a Key Process for Cancer Progression and Metastasis
Date:5/26/2011

SAN DIEGO, May 26, 2011 /PRNewswire/ -- Tragara Pharmaceuticals, Inc. announced today that apricoxib (Capoxigem®, TG01), its novel COX-2 inhibitor in development for select cancer types, demonstrated reversal of the epithelial-mesenchymal transition (EMT) in xenograft models of several types of solid tumors. These data results were presented at the 2011 American Society for Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium and the 2011 American Association for Cancer Research (AACR) Annual Meeting and demonstrate that apricoxib potently inhibits the activity of COX-2 and COX-2 derived prostaglandin E2 (PGE2), which in turn mediates EMT and the associated progression and metastasis of solid tumors.

"Reversal of EMT may provide several clinical benefits to patients with non-small cell lung cancer and pancreatic cancer," stated Sara Zaknoen, M.D., chief medical officer, Tragara Pharmaceuticals, Inc. "Patients may experience longer survival due to effects of EMT reversal on metastases and the cancer stem cell, and benefit from the reversal of resistance to drugs such as erlotinib."

Tragara has completed two phase II clinical trials of apricoxib. Results from the APRiCOT-L trial, a biomarker-based, phase II, randomized, placebo-controlled study of apricoxib in combination with erlotinib in non-small cell lung cancer, will be presented on June 6th at the ASCO meeting in Chicago. A second phase II study of apricoxib in combination with gemcitabine and erlotinib has completed enrollment and is currently being analyzed.

"COX-2 has been implicated in EMT, so we were gratified to see robust reversal of EMT resulting from apricoxib treatment in xenograft models of pancreatic, colon, and head and neck cancers," stated Francis Burrows, Ph.D., head of oncology biology, Tragara Pharmaceuticals, Inc.  "This effect was associated with profound inhibition of metastasis in orthotopic cancer models but, interestingly, apricoxib-mediated EMT re
'/>"/>

SOURCE Tragara Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)...  Abaxis, Inc. (NasdaqGS: ABAX ), a ... the medical, research, and veterinary markets worldwide and providing ... in the United States , announced ... acquire 100% of QCR & Trio Diagnostics Limited, a ... The transaction closed on November 17, 2014. ...
(Date:11/21/2014)... , 21. November 2014 /PRNewswire/ ... hat heute bekannt gegeben, dass die ... EMA) die Kennzeichnung als Orphan-Medizinprodukt an ... des Unternehmens zur Behandlung von Fibrodysplasia ... seltene, stark beeinträchtigende genetische Krankheit, die ...
(Date:11/21/2014)... N.Y. , Nov. 21, 2014  Cardinal Health, ... world,s largest health care services companies, and Henry Schein, ... provider of health care products and services to office-based ... the companies have entered into a long-term strategic agreement ... product offerings to office-based medical practices.  This strategic agreement ...
Breaking Medicine Technology:Abaxis Acquires UK-based Distribution Organization 2Abaxis Acquires UK-based Distribution Organization 3Abaxis Acquires UK-based Distribution Organization 4Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 2Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 3Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 2Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 3Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 4Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 5
... , SEELZE, Germany, Dec. ... today a multi-year distribution agreement with Pro-Lab Laboratuar Teknolojileri, ... in Turkey. , Burdick & Jackson solvents are used ... discovery and evaluation process. , "The annual growth rate ...
... ... Channel 9 recently reported that the " Help is ... financially-struggling Floridians access information on patient assistance programs that provide prescription medicines ... bus, which is part of the Partnership for Prescription Assistance ...
Cached Medicine Technology:Honeywell and Pro-Lab Sign Distribution Agreement for Laboratory Chemicals in Turkey 2Honeywell and Pro-Lab Sign Distribution Agreement for Laboratory Chemicals in Turkey 3'Help is Here Express' in Orlando to Help Floridians Afford Medicine 2
(Date:11/22/2014)... November 22, 2014 The topic of ... of block retaining walls. The article states that, “While they ... several necessary steps that go into creating this powerful look.” ... a retaining wall is choosing which kind of block matches ... , B&D Rockeries says, “The two main options are concrete ...
(Date:11/22/2014)... (PRWEB) November 22, 2014 Recently, UWDress.com ... wedding guest dresses . In addition, the company ... products. , As a leading online supplier of ... of beautiful outfits. The unusual best wedding guest gowns ... Besides the amazing designs, this new selection is famous ...
(Date:11/22/2014)... (PRWEB) November 22, 2014 A ... was announced today which safely detects and identifies ... frequency radio waves. Developed by RHT SpectraSafe, the ... hosts broad applications in other areas including medical, ... security. , Using high frequency radio waves that ...
(Date:11/22/2014)... A Xarelto lawsuit has been filed on behalf ... million in damages from the makers and marketers of the ... the woman began using Xarelto in March 2012 and used ... she suffered life-threatening bleeding in July 2012 and as a ... emotional distress. The lawsuit purports that the woman’s injuries are ...
(Date:11/22/2014)... HealthDay Reporter FRIDAY, Nov. 21, 2014 (HealthDay ... in an ambulance by a neurologist equipped with a CT ... patients get the clot dissolver -- tissue plasminogen activator (tPA) ... noted. For the best outcome, the drug needs to be ... researchers said. "The so-called ,golden hour, is associated with ...
Breaking Medicine News(10 mins):Health News:5 Step Installment of Block Retaining Walls is Topic of Latest Article by B&D Rockeries 2Health News:Best Wedding Guest dresses Introduced by UWDress.com 2Health News:RHT SpectraSafe announces a Radical New Airport Security Technology that Is More Effective, Less Invasive 2Health News:Xarelto Lawsuit News: Woman Seeks $10 Million in Damages For Alleged Bleeding Side-Effect Due To Xarelto Use 2Health News:Xarelto Lawsuit News: Woman Seeks $10 Million in Damages For Alleged Bleeding Side-Effect Due To Xarelto Use 3Health News:Xarelto Lawsuit News: Woman Seeks $10 Million in Damages For Alleged Bleeding Side-Effect Due To Xarelto Use 4Health News:Special Ambulance Delivers Vital Stroke Care More Quickly 2Health News:Special Ambulance Delivers Vital Stroke Care More Quickly 3
... a National CompetitionCINCINNATI, March 31 The Prilosec OTC(R) ... nation and it is giving fans the opportunity to ... win tickets to upcoming NASCAR(R) Sprint Cup Series(TM) races. ... across the country will be firing up their grills ...
... ... be available in one year-,BELLEVILLE, ON, March 31 ... a research-based, technology-driven Canadian biopharmaceutical company, today announced ... Phase III registration trial evaluating Urocidin(TM) in the ...
... of potential medical problemsHONOLULU, March 31 A new ... there are significant benefits for patients and nurses when ... "The outcomes were definitive," stated Dr. Patrick Sullivan, President ... monitoring provides an early alert to RNs about potential ...
... Health Care Provides Extensive Services & SupportSAN FRANCISCO, March ... of in home support and recovery services has announced ... Interim HomeStyle Services first opened its San Francisco ... to help people remain independent as they age or ...
... Wilhelm uses latest technology to give patients the ability to improve smile ... ... Dr. Wilhelm, DMD MSD, announced today that he is providing patients with ... giving patients the appearance of a perfect set of teeth and an ...
... Urgent Care Center. Hoboken residents now have much needed option for treatment ... ... -- Hoboken families now have a convenient place to go for most ... Hoboken,s first Urgent Care center and a medical facility like no other ...
Cached Medicine News:Health News:Prilosec OTC(R) Fires Up A BBQ Tour for NASCAR(R) Fans 2Health News:Prilosec OTC(R) Fires Up A BBQ Tour for NASCAR(R) Fans 3Health News:Prilosec OTC(R) Fires Up A BBQ Tour for NASCAR(R) Fans 4Health News:Bioniche Completes Recruitment in First Phase III Clinical Trial with Urocidin(TM) 2Health News:Bioniche Completes Recruitment in First Phase III Clinical Trial with Urocidin(TM) 3Health News:Study Shows Patients & Nurses Benefit From Continuous Vigilance Monitoring 2Health News:Nation's Largest Home Care Provider Welcomes New Management Team to San Francisco Office 2Health News:Dr. Wilhelm, DMD MSD, Makes Clients Smile with New Easy Smile Dental Appliance 2Health News:Dr. Wilhelm, DMD MSD, Makes Clients Smile with New Easy Smile Dental Appliance 3Health News:PromptMD Announces the Opening of their First Urgent Care Center at 309 First Street in Hoboken 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: